Artivion, Inc. (NYSE:AORT) Stock Has Average Price Target of $39.00 According to Brokerages

Artivion, Inc. (NYSE:AORT) has been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $39.00.

Several analysts have commented on the stock. Wall Street Zen cut shares of Artivion from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Canaccord Genuity Group cut their price target on Artivion from $40.00 to $30.00 and set a “buy” rating on the stock in a research note on Friday. Weiss Ratings lowered Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Needham & Company LLC reaffirmed a “buy” rating and set a $44.00 price objective on shares of Artivion in a research note on Monday, July 20th. Finally, Jefferies Financial Group initiated coverage on Artivion in a report on Tuesday, October 20th. They issued a “buy” rating and a $31.00 price objective for the company.

Artivion Trading Down 20.1%

AORT stock opened at $20.23 on Friday. The company has a quick ratio of 2.51, a current ratio of 3.47 and a debt-to-equity ratio of 0.82. Artivion has a twelve month low of $19.16 and a twelve month high of $48.25. The company has a market cap of $986.66 million, a P/E ratio of -56.21 and a beta of 1.31. The business has a fifty day moving average of $23.55 and a 200-day moving average of $28.98.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Thursday, November 5th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.14. Artivion had a positive return on equity of 5.11% and a negative net margin of 3.65%. The business had revenue of $123.79 million for the quarter, compared to analysts’ expectations of $120.97 million. As a group, equities research analysts expect that Artivion will post 0.37 EPS for the current year.

Insiders Place Their Bets

In other news, CEO James P. Mackin sold 70,000 shares of the company’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $28.95, for a total value of $2,026,500.00. Following the completion of the sale, the chief executive officer directly owned 877,275 shares of the company’s stock, valued at $25,397,111.25. This represents a 7.39% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Andrew M. Green sold 11,480 shares of the company’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $24.97, for a total value of $286,655.60. Following the completion of the sale, the senior vice president directly owned 40,160 shares of the company’s stock, valued at approximately $1,002,795.20. This trade represents a 22.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 90,460 shares of company stock worth $2,557,366. Insiders own 6.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Diversified Trust Co bought a new position in Artivion in the third quarter valued at approximately $297,000. Aberdeen Group plc bought a new stake in shares of Artivion during the third quarter worth $11,891,000. Allworth Financial LP raised its holdings in shares of Artivion by 2,048.3% during the third quarter. Allworth Financial LP now owns 1,246 shares of the company’s stock worth $28,000 after acquiring an additional 1,188 shares during the period. Russell Investments Group Ltd. raised its holdings in shares of Artivion by 9.5% during the third quarter. Russell Investments Group Ltd. now owns 120,333 shares of the company’s stock worth $2,746,000 after acquiring an additional 10,426 shares during the period. Finally, Maryland State Retirement & Pension System acquired a new stake in shares of Artivion during the third quarter worth $245,000. Institutional investors own 86.37% of the company’s stock.

Key Stories Impacting Artivion

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Q3 revenue rose 9% year over year to $123.8 million, exceeding analysts’ estimates of about $121 million. The company also reported non-GAAP EPS of $0.08, above a consensus estimate of a $0.06 loss cited in one report. Artivion Q3 results
• Positive Sentiment: Artivion forecast 2026 revenue of $484 million to $492 million and said it is preparing to launch its NEXUS product in January 2027, offering potential future growth catalysts. Revenue outlook and NEXUS launch
• Neutral Sentiment: Citizens JMP lowered its price target to $42 from $48 but maintained a Market Outperform rating; the revised target still implies substantial upside from the cited share price. Citizens JMP recommendations
• Negative Sentiment: Canaccord also cut its target, to $30, adding to concerns about analysts’ reassessment of the stock’s outlook. Canaccord price-target change
• Negative Sentiment: Despite revenue growth, Artivion posted a $7.9 million GAAP net loss, and adjusted EBITDA fell 8% to $22.5 million. Zacks also reported that the $0.08 quarterly EPS missed its $0.11 estimate, highlighting that earnings expectations vary by source and may weigh on sentiment. Zacks earnings analysis

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a medical device and biotechnology company focused on developing and commercializing products used in cardiac and vascular surgery. Its portfolio includes implantable devices, surgical sealants, and human tissue products designed to treat diseases of the heart, aorta, and peripheral blood vessels.

The company’s products include On-X mechanical heart valves, aortic and vascular grafts, BioGlue surgical adhesive, and stent graft systems for aortic repair. Artivion also provides tissue preservation services and distributes cardiac and vascular allografts for use in reconstructive procedures.

Artivion was formerly known as CryoLife, a company founded in 1984, and adopted the Artivion name in 2021 to reflect its broader focus on aortic and cardiac care.